Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 3, 2011, Pages 179-185

  Yeh, Yu Chen ^a   McDonnell, Anne ^b   Klinger, Elissa ^a   Fowler, Bridget ^c   Matta, Lina ^a   Voit, Daniel ^a   Reddy, Prabashni ^a  

^a PARTNERS HEALTHCARE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

5HT3 receptor antagonists; chemotherapy induced nausea and vomiting; intraperitoneal cisplatin; ondansetron; palonosetron; utilization

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DYSPNEA; ELECTROLYTE DISTURBANCE; EMERGENCY CARE; FEMALE; HOSPITAL READMISSION; HUMAN; HYPOKALEMIA; HYPOVOLEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTPATIENT CARE; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; SYNCOPE; UTERINE TUBE CARCINOMA;

ADULT; AGED; AMBULATORY CARE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BOSTON; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; EMERGENCY SERVICE, HOSPITAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HEALTH RESOURCES; HUMANS; ISOQUINOLINES; LENGTH OF STAY; MIDDLE AGED; NAUSEA; ONDANSETRON; OVARIAN NEOPLASMS; PATIENT READMISSION; PREMEDICATION; QUINUCLIDINES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN ANTAGONISTS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 79953310418     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210366491     Document Type: Article

References (13)

1. Armstrong DK, Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 ; 354: 34-43. (Pubitemid 43048949)
2. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecological Oncology Group study. Gyn Onc 2006 ; 100: 27-32. (Pubitemid 41815045)
3. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006 ; 24: 2932-2947. (Pubitemid 46630595)
4. Red Booktm. Drug references. New York, NY: Thomson Reuters, 2009.
5. Yeh YC, Reddy P., Clapp M., and Churchill W. Systematic review of palonosetron in chemotherapy-induced nausea and vomiting. In: International Society for Pharmacoeconomics and Outcomes Research. Toronto, Canada, May 2008.
6. Aloxi. Prescribing information. Bloomington MN: MGI Pharma Inc., September 2007.
7. Eisenberg P., Figueroa-Vadillo J., Zamora R., et al. 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003 ; 98: 2473-2482. (Pubitemid 37466663)
8. Gralla R., Lichinitser M., Van Der Vegt S., et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003 ; 14: 1570-1577. (Pubitemid 37304615)
9. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006 ; 17: 1441-1449. (Pubitemid 44400384)
10. FDA Reviewers' comments on Aloxi (Palonosetron Hydrochloride) injection http://www.fda.gov/cder/foi/nda/2003/21-372-Alox-Statr.pdf (accessed 10 December 2007 ).
11. Zofran. Prescribing information. Research Triangle Park, NC 27709, GlaxoSmithKline, October 2009.
12. Kytril. Prescribing information. Nutley, NJ 07110, Roche Laboratories Inc., October 2009.
13. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemetics. Version 1. 2007.